FDA — authorised 4 September 2015
- Application: NDA200671
- Marketing authorisation holder: HESP
- Local brand name: DURLAZA
- Indication: CAPSULE, EXTENDED RELEASE — ORAL
- Status: approved
FDA authorised Durlaza™ on 4 September 2015
Yes. FDA authorised it on 4 September 2015.
HESP holds the US marketing authorisation.